Drug
Dolutegravir Abacavir Lamivudine
Dolutegravir Abacavir Lamivudine: highest development phase Phase 1, developed by Shionogi. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Shionogi
Trials
| Drug | Phase | Indication |
|---|---|---|
| Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg NCT01622790 | Phase 1 | Infection, Human Immunodeficiency Virus |
Latest
No recent events.
Follow Dolutegravir Abacavir Lamivudine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.